- Home
- FNWD vs UNCY Comparison
FNWD vs UNCY Comparison
Compare FNWD & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FNWD | UNCY |
|---|---|---|
| Founded | 1994 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.2M | 145.3M |
| IPO Year | 1996 | 2021 |
Fundamental Metrics
Financial Performance| Metric | FNWD | UNCY |
|---|---|---|
| Price | $36.30 | $6.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $34.00 | ★ $44.50 |
| AVG Volume (30 Days) | 4.7K | ★ 398.1K |
| Earning Date | 04-29-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.32% | N/A |
| EPS Growth | N/A | ★ 56.25 |
| EPS | ★ 1.88 | N/A |
| Revenue | N/A | ★ $675,000.00 |
| Revenue This Year | $17.40 | N/A |
| Revenue Next Year | $5.44 | N/A |
| P/E Ratio | $19.31 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $26.46 | $0.45 |
| 52 Week High | $39.99 | $7.57 |
Technical Indicators
Market Signals| Indicator | FNWD | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 44.01 | 43.70 |
| Support Level | $35.25 | $5.90 |
| Resistance Level | $38.75 | $6.82 |
| Average True Range (ATR) | 0.79 | 0.28 |
| MACD | -0.09 | -0.07 |
| Stochastic Oscillator | 0.00 | 11.27 |
Price Performance
Historical ComparisonAbout FNWD Finward Bancorp
Finward Bancorp is a bank holding company, which engages in the provision of financial services. It offers products and services related to Personal Banking, Cash Management, Saving Account, ebanking, Wealth Management, and Insurance Services. It is engaged in the business of attracting deposits from the general public and the origination of loans, mostly upon the security of single-family residences and commercial real estate, construction loans, commercial business loans, and municipal loans. Geographically, the activities are carried out through the United States.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.